Citigroup cuts Ultragenyx Pharma price target to $28.00
Citigroup cut its price target for Ultragenyx Pharma to $28.00 per share from $58.00, while maintaining a Buy rating, according to Benzinga.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.